Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Leinco Technologies Inc Anti-Human HLA-A, B, C (MHC class I) In Vivo GOLD; Clone W6/32; Isotype: Mouse IgG2a
SDP

Supplier:  Leinco Technologies Inc H263100 MG

Encompass_Preferred

Specificity: Clone W6/32 recognizes human major histocompatibility complex (MHC) class I, HLA-A, B, and C. Antigen Distribution: MHC class I antigens associated with β2-microglobulin are expressed by all human nucleated cells. HLA-A, B, C is present on most nucleated cells of humans and old world monkeys. Background: MHC class I molecules are part of the Ig superfamily and are involved in the presentation of antigens to CD8+ T cells. HLA-A, B, C plays a central role in cell-mediated immune responses and tumor surveillance. Applications: (WB) Clone W6/32 recognizes residues in the N terminus of the human β2-microglobulin molecule. Leinco’s In vivo GOLDTM and In vivo PLATINUMTM functional antibodies are manufactured in an animal free facility using only In vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Catalog No. 50-190-6349


May include imposed supplier surcharges.
Only null left
Add to Cart

Product Content Correction

The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Your feedback has been submitted: Thank you for helping us improve our website.